risk adapted treatment childhood, minimal residual disease,
Abstract Background
In study CoALL 06-97 in vitro sensitivity towards prednisolone, vincristine and asparaginase was implemented as a new additional risk parameter for treatment stratification of children with acute lymphoblastic leukemia. In parallel in vivo treatment response was assessed by minimal residual disease in a subset of patients (n=224). Here we report the long-term impact of in vitro sensitivity based risk stratification according to survival and compare the results of in vitro sensitivity with in vivo response.
Design and Methods
Patients with a sensitive in vitro profile were treated by a reduced intensity protocol (n=167) whereas patients defined as Low Risk according to conventional parameters but with a resistant in vitro profile underwent an intensified therapy (n=47).
Results
At a median follow-up of 6.8 years event-free survival was 0.80±0.03 for patients with a sensitive, 0.73±0.03 with an intermediate and 0.67±0.08 with a resistant profile (p=0.015). Overall, treatment results of the cases stratified according to in vitro sensitivity were similar to the historical control stratified based on conventional risk factors.
Minimal residual disease at the end of induction was a strong predictor of outcome in B -Precursor and T-cell acute lymphoblastic leukemia. There was no correlation between in vitro and in vivo treatment response in B-Precursor (r spearman =0.13; p=0.15) in contrast to T-cell acute lymphoblastic leukemia (r spearman =0.63; p<0.001)
Conclusion
Moderate reduction in treatment intensity for patients with a sensitive in vitro profile was possible without jeopardizing treatment outcome. However, in vitro drug testing was affected by a decrement in risk predictive power over time and revealed no correlation with in vivo assessment of minimal residual disease in B-Precursor acute lymphoblastic leukemia. Therefore it was abandoned in favor of the assessment of in vivo response in subsequent CoALL trials.
Introduction
Traditionally, antileukemic therapy has been adjusted to risk factors such as age, white blood cell count, immunological phenotype, specific chromosomal alterations and response to therapy. In vitro [1, 2, 3, 4] and in vivo [5, 6, 7, 8] drug resistance testing (e.g. by a colorimetric-based MTT-assay or a fluorescence-based FMCA assay) were established with the goal to strengthen the power of risk prediction in childhood ALL.
Several groups studied the prognostic value of drug resistance testing in children with newly diagnosed ALL. Resistance to single agents such as glucocorticoids, vinca alkaloids, L-asparaginase and anthracyclines was shown to be associated with unfavorable immunophenotypic and cytogenetic subtypes of ALL as well as an older age of patients [9, 10] . Moreover, resistance of leukemic cells to single agents predicted unfavorable short-term (induction failure) and long-term (relapse) clinical outcome [1, 11, 12, 13] .
A drug resistance profile, combining resistance data of 3 drugs was shown to be more discriminative for clinical outcome than that predicted by single agents [3, 11, 13, 14] . Most discriminative for clinical outcome was a profile combining cellular resistance towards prednisolone, vincristine and L-asparaginase. In Japanese, Polish and Dutch studies, patients with a resistant profile suffered more often from induction failure or relapse than patients with an intermediate or sensitive profile. In multivariate analyses, the predictive value of the drug resistance profile remained highly significant suggesting a potential use as a prognostic factor for newly diagnosed ALL of childhood [3, 12, 14] .
The value of a drug resistance profile as risk predictive tool was confirmed in a [19, 20] and one prospective study [21] investigating a potential relationship between MRD and in vitro chemoresistance.
They revealed a weak correlation between MRD and response to single drugs such as prednisolone and doxorubicin [21] . Here we describe the relevance of the in vitro (PVA Score) and in vivo (MRD) treatment response for the prediction of outcome in a large cohort of 224 children uniformly treated according to the CoALL 06-97
protocol.
Design and methods

Assessment of the PVA score
At diagnosis leukemia samples from bone marrow (BM) and/or peripheral blood (PB)
were tested for in vitro cytotoxicity based on the methyl-thiazol-tetrazolium (MTT) assay which has been described before in detail [16] . Briefly, leukemic cells were incubated in the absence (control) or presence of six different concentrations of drug in duplicate (prednisolone: range 0.06 to 250 µ g/ml; vincristine: range 0.05 to 50µg/ml; asparaginase range 0.003 to 10 IU/ml). After four days of culture at 37ºC in humidified air containing 5 % CO 2 , 0.45mg/mL of 3-[4.5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazoliumbromide (MTT) was added. Formazan crystals, produced by viable cells only, were dissolved in acidified isopropanol and quantified by spectrophotometry at 562 nm. In vitro cytotoxicity of prednisolone, vincristine and Lasparaginase (PVA) was determined. For each patient a three-drug resistance profile was generated that combined the results of the individually tested drugs into one score, i.e. PVA score, identical to what has been previously described [16] . In short, high sensitivity towards a drug was scored as 1, intermediate sensitivity was scored as 2 and resistance was scored as 3. Combining the separate scores of prednisolone, vincristine and L-asparaginase of each patient resulted in an individual PVA score that varied between 3 (sensitive to all 3 drugs) and 9 (resistant to all 3 drugs).
Analysis of minimal residual disease (MRD)
For MRD analysis, DNA was isolated from bone marrow mononuclear cells obtained at diagnosis, day (d) 15 of the induction phase, at the end of induction (d29) and at week 12 for low and week 15 for high risk patients.
PCR studies for MRD analysis were performed with IgH and TCR gene rearrangements as targets. DNA samples from diagnosis were screened for clonal products using the BIOMED-2 primers for Ig deleting element (Kde), complete and incomplete TCR , TCR and TCRß gene rearrangements. IgH rearrangements were identified using 7 VH region and 1 JH consensus primer. Products were analyzed for clonality on 6% acrylamide gels and positive products were further processed.
Junctional regions of clonal products were sequenced directly and patient specific junctional regions were identified for generation of allele specific PCR primers.
Biclonal or biallelic products were cloned using the TOPO-TA cloning kit (Invitrogen) and then processed adequately for generation of suitable patient specific primers.
Subsequently PCR-MRD targets were tested for specificity and sensitivity to reach a sensitivity and a quantifiable range of 1x10 -4 for at least two targets. Real-time quantitative PCR (RQ-PCR) was performed and interpreted according to the guidelines developed within the European Study Group for MRD detection in ALL (ESG-MRD ALL) [22] . In detail, sequence specific TaqMan probes were used on a LC480 machine (Roche). Tenfold serial dilutions of diagnostic DNA were prepared in pooled peripheral blood DNA extracted from at least five healthy donors.
Quantification was performed using this standard curve and triplicates of follow-up samples including 500 ng DNA in each reaction. 
Low risk patients
All Low Risk Patients received an identical consolidation therapy, followed by 6-mercaptopurine (MP) daily for four weeks and four doses of intrathecal MTX (CNS phase). In reinduction for Low Risk Reduced (LR-R) patients the doses of adriamycin (ADR) and dexamethasone (DEX) were halved (figure 2). Thus LR-R patients received only one dose of ADR and 7 days DEX, whereas Low Risk Standard (LR-S) patients received two doses ADR and 14 days DEX. All LR patients received the second part of reinduction (figure 2).
High risk and low risk intensified patients
Low Risk Intensified and High Risk Standard patients underwent the same treatment.
All patients received an identical consolidation therapy, followed by daily 6-MP for No treatment intervention according to the result of minimal residual disease was taken.
Maintenance therapy, consisting of daily 6-MP and weekly MTX per oral doses, was administered until 104 weeks after diagnosis. Three, 6 and 9 months after the start of maintenance therapy all patients without CNS-irradiation received two doses of intrathecal MTX.
Statistical analysis
Each year patient data were collected on protocol-specific forms and reviewed before data entry by the trial data monitoring board, which also performed the statistical analysis. Probability of event-free survival (pEFS) was estimated according to Kaplan
Meier and compared between subgroups using the log-rank test [23] . pEFS was defined as the time from diagnosis to the first outcome event, which were remission failure (no remission until day 56), induction death, relapse, death from any cause in remission or a second malignancy. pDFS was defined as the time from complete remission to first relapse. Cumulative incidence of relapse was calculated by the method of Kalbfleisch and Prentice and compared using Gray's test [24] . Survival estimates are given as 10-year estimate with standard error (±SE) . For multivariate analysis of pEFS the Cox regression analysis was used [25] . The models for multiple analyses included age (cutoff 10 years), WBC (cutoff 25000/µl), immunophenotype 
Results
Overall treatment results
The probability of EFS at 6 years and 10 years of follow-up for all 667 patients was 0.77±0.02 and 0.75 ±0.02, respectively. The median follow-up of patients at risk was 6.8 years (range 5.1-11.0 years). Between LR and HR patients the prognosis (10 year pEFS 0.81±0.02 vs 0.67±0.03; p=0.001) and incidence of relapse (0.16±0.02 vs 0.25±0.03; p=0.001) differed significantly.
There was no significant difference in outcome and incidence of relapse in patients with or without measurable PVA score (10 year pEFS 0.73 ±0.02 versus 0.76 ±0.03; p=0.985).
Five of 667 children (0.75%) died during induction therapy and 9 patients (1.3%; 3 LR and 6 HR patients) died on therapy in remission due to infectious complications.
Thirty-seven patients underwent a stem cell transplantation, 12 of whom received a graft from a matched related and 25 of whom were transplanted from a matched unrelated donor. Only one HR patient received a SCT based on a PVA score of 8 without other criteria qualifying for SCT. Six HR patients died after stem cell transplantation in first remission due to therapy-related complications and two patients died several years after completion of therapy due to accidents. Thirty-six patients were not in remission on day 29 but had achieved remission by day 56. All these patients were treated according to the High Risk Standard protocol. Remission failure defined as no remission on day 56 was only seen in three HR patients. Six patients developed a second malignancy. The distribution of events is presented in Risk patients (p=0.0004). T -ALL patients presented more frequently with the very ends of the PVA score,i.e. score 3 and 4 was measured in 45.3% T-ALL compared to 29.6% of B -Precursor patients whereas score 8 and 9 was determined in 18.7% of T-ALL patients and 6.7% of B-Precursor patients (table 2) . In patients who failed to achieve remission at the end of induction there was a significant trend to higher PVA scores compared to patients being in remission on day 29 (Chi square p= 0.0001).
Fourteen out of 39 patients (35%) with induction failure had a PVA score ≥7 compared compared to 15 % within the whole group and only 4 out of 39 patients (10%) had a PVA score of 3+4 compared to 25% of the patients in the entire group.
Treatment outcome of patients stratified by PVA profile 
Predictive value of resistance to L-asparaginase
We also looked at the prognostic value regarding the sensitivity towards each single The subset of B-Precursor patients in whom MRD was measured did not differ from the whole cohort in respect of gender, age, initial WBC or chromosomal translocation.
Prognostic value of MRD
Minimal residual disease at the end of induction was a strong predictor of outcome.
In 
Multivariate analyses
When a Cox regression analysis of EFS was applied taking into account the PVA score and traditional risk factors, a prognostic significance was identified for initial WBC and high risk features such as induction failure and adverse chromosomal translocations. PVA score 3+4 was of borderline significance (p=0.05). The Cox regression analysis by single agents showed a strong prognostic power for asparaginase (p = 0.0001); initial WBC and high risk features retained significance.
When integrating MRD in this model only low MRD levels at the end of induction (d29) remained significant (p=0.01) (table 3a+b).
Discussion
Since the introduction of the first antileukemic agent by Sidney Farber in 1948 [27] , cure rates have increased steadily for childhood ALL [28] [29] [30] [31] [32] . However, the intensity of treatment protocols has reached a high level, and there has been concern that a substantial proportion of patients was being overtreated due to the lack of a refined risk assignment which relied on traditional risk factors such as initial white blood The small number of patients in the previous study however does not allow for a test of equivalence.
With longer follow-up of the original CoALL 05-92 cohort it became apparent that the PVA score predicted early rather than late relapses leading to a decrement of the prognostic power over time [16] . This observation also holds true for study CoALL 06-97. The PVA score was of significant prognostic value exclusively in HR patients who generally develop a relapse within the first two years after completion of therapy. However, since therapy was intensified only in Low Risk patients with a high PVA score by treating them as High Risk patients the prognostic impact of the PVA in the LR group may score may disappear.
The prognostic impact of in vitro drug sensitivity testing per se is restricted by the selection of drugs. Analysis of the prognostic impact by the single drugs of the PVA score revealed that in vitro sensitivity towards asparaginase alone was still an independent predictor of relapse in both risk groups, suggesting that the current therapy was not suitable to overcome L-asparaginase resistance. The observation that the asparaginase score loses its predictive power when MRD was integrated in the model of multivariate analysis might be due to a selection of identical patients by both methodologies but a stronger predictive power of MRD. In vitro sensitivity towards prednisolone was associated with a superior prognosis only in a univariate analysis. A prognostic impact of in vitro sensitivity towards vincristine could not be found. This suggests that the impact of resistance towards these two drugs on outcome was lost upon treatment adaption. Previous studies reported a significant impact of the in vitro sensitivity towards VCR and PRED but the number of patients enclosed was substantially smaller compared to the patients in the present CoALL study, which may also account for the conflicting results [1, 2, 3, 9] .
Recently, it has become increasingly clear, that immunologic control mechanisms play a pivotal role in the maintenance of long-term remission. Blasts that remain unrecognized by the immune system or hide in immunological niches may give rise to relapse. These host specific factors are not adequately reflected by in vitro drug sensitivity test systems, but might well contribute to the treatment response measured in vivo, whereas MRD measurements also accounts for host pharmacokinetics, pharmacodynamics and pharmacogenetics.
This note is in line with data from a substantial number of studies showing that measurement of MRD within the first 4-5 weeks of treatment is highly predictive for the outcome of children with acute lymphoblastic leukemia [5, 6, 7, 17, 18] . In Bprecursor ALL patients the NOPHO group observed a significant correlation between MRD level at day 15 (i.e. after induction) and in vitro sensitivity against prednisolone, vincristine and doxorubicin, drugs that were used in the induction. In the presented CoALL 06-97 trial a correlation between in vitro drug resistance and in vivo response to chemotherapy could only be found in T-ALL patients but not in B-Precursor patients. The PVA score as determined in CoALL 05-92 and 06-97 trials comprises the sensitivity against prednisolone, vincristine and asparaginase, but the latter -not given in COALL induction -was the only drug which strongly correlates with MRD in T -ALL patients.
In summary, treatment reduction in COALL 97 was feasible for patients with a sensitive in vitro drug testing profile without introducing an increased risk of relapse.
Beside the immediate prevention of life-threatening infectious complications, this treatment reduction is anticipated to exert its beneficial impact in the long run on late adverse effects such as anthracycline induced cardiotoxicity.
Surprisingly, no correlation was found between the in vitro response and the minimal residual disease in vivo under treatment in B-precursor ALL. Although a simple, up front and low cost diagnostic tool, in vitro drug testing has been abandoned in favor of the more predictive, but somewhat sophisticated in vivo evaluation of MRD in the ongoing COALL trial which yields a clear cut and robust separation of risk groups.
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